tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Silence Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsSilence Therapeutics Reports Q3 2025 Financial Results
4M ago
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
Premium
Ratings
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
4M ago
Silence Therapeutics reports Q3 EPS (15c), consensus (21c)
Premium
The Fly
Silence Therapeutics reports Q3 EPS (15c), consensus (21c)
4M ago
Michael Davidson Resigns from Silence Therapeutics Board
PremiumCompany AnnouncementsMichael Davidson Resigns from Silence Therapeutics Board
7M ago
Buy Rating for Silence Therapeutics: Promising siRNA Therapies and Strategic Pipeline Prioritization
Premium
Ratings
Buy Rating for Silence Therapeutics: Promising siRNA Therapies and Strategic Pipeline Prioritization
7M ago
Private Markets: Canva draws attention as IPO candidate following Figma debut
Premium
The Fly
Private Markets: Canva draws attention as IPO candidate following Figma debut
7M ago
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
PremiumRatingsPromising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
9M ago
Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating
Premium
Ratings
Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating
9M ago
Silence Therapeutics presents additional Phase 1 data highlighting Divesiran
Premium
The Fly
Silence Therapeutics presents additional Phase 1 data highlighting Divesiran
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100